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Abstract 
Background: Obstructive sleep apnea (OSA) and type 2 diabetes (T2D) are associated with endothelial dysfunction a 
main predictor of late cardiovascular (CV) events. Despite the high prevalence of OSA in patients with T2D, the impact 
of OSA severity on endothelial function has not been clearly elucidated. The aim of this cross-sectional study was to 
determine whether increasing OSA severity is associated with poorer endothelial function in patients with T2D.
Methods: 140 patients with T2D and no overt CV disease underwent polysomnography, peripheral arterial tonom-
etry, clinic blood pressure (BP) measurement, biological assessment for CV risk factors, daytime sleepiness and health 
related quality of life (HRQL) questionnaires. The following commonly used cut-offs for apnea-hypopnea index (AHI) 
were used to define 3 categories of disease severity: AHI < 15 (no OSA or mild OSA), 15 ≤ AHI < 30 (moderate OSA), 
and AHI ≥ 30 (severe OSA). The primary outcome was the reactive hyperemia index (RHI), a validated assessment of 
endothelial function.
Results: 21.4% of patients had moderate OSA and 47.6% had severe OSA. Increasing OSA severity and nocturnal 
hypoxemia were not associated with a significant decrease in RHI. Endothelial dysfunction (RHI < 1.67) was found 
in 47.1, 44.4 and 39.2% of patients with no OSA or mild OSA, moderate OSA and severe OSA, respectively (p = 0.76). 
After adjustment for confounders including body mass index, increasing OSA severity was associated with higher 
systolic BP (p = 0.03), lower circulating levels of adiponectin (p = 0.0009), higher levels of sP-selectin (p = 0.03), lower 
scores in 3 domains of HRQL including energy/vitality (p = 0.02), role functioning (p = 0.01), and social functioning 
(p = 0.04).
Conclusions: Moderate to severe OSA is very common but has no impact on digital micro-vascular endothelial func-
tion in patients with T2D.
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Background
Endothelial dysfunction is a pathophysiological determi-
nant of atherogenesis that occurs at the early stages of 
coronary artery disease [1] and predicts the occurrence of 
cardiovascular (CV) events in at-risk subjects [2]. Flow-
mediated dilatation (FMD) of the brachial artery has been 
extensively used as a noninvasive measure of endothelial 
function. However, the FMD technique is time-consum-
ing and requires a careful learning curve, which limits its 
routine application in large multicenter studies. Measur-
ing endothelial function by peripheral arterial tonom-
etry (PAT) has recently gained increased attention, as 
the reactive hyperemia index (RHI) measured by PAT is 
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a validated marker of endothelial function [3]. Validation 
studies have demonstrated that RHI is correlated with 
coronary micro-vascular function in patients with early 
atherosclerosis [4] and predicts CV events [5–7]. Recent 
study underlined the relationship between immune-
inflammatory markers, endothelial and arterial stiffness 
index in patients with acute ischemic stroke, also sug-
gesting the use of a combination of PAT and arterial stiff-
ness indexes to better categorize patients with ischemic 
stroke [8, 9]. Nitric oxide (NO) plays an important role in 
digital reactive hyperemia [10]. Kuvin et al. [11] found a 
significant correlation (r = 0.55, p < 0.0001) between RHI 
and FMD in 89 subjects, 38% of whom had a history of 
coronary artery disease. RHI was also significantly corre-
lated with FMD (r =  0.47; p  <  0.001) in non-obese and 
non-smoker subjects free of overt CV disease [12]. In 
the Framingham health study, RHI correlated with tradi-
tional CV risk factors but the association with FMD was 
not significant in multivariable-adjusted analyses [13].
The obesity pandemic is associated with an increasing 
prevalence of type 2 diabetes (T2D) and obstructive sleep 
apnea (OSA). T2D carries a substantially increased risk of 
macro and micro-vascular complications, including cor-
onary artery disease, nephropathy, retinopathy and non-
healing foot ulcers [14, 15]. Endothelial dysfunction is 
important in the pathogenesis of diabetic angiopathy due 
to increased vascular tone, vascular inflammation and 
oxidative stress [15–17]. Several studies demonstrated 
that micro-vascular endothelial function assessed by the 
RHI is impaired in patients with T2D and improved by 
dietary of pharmacological interventions [15, 18–22]. In 
a cross-sectional study including 183 patients undergoing 
coronary angiography, diabetic patients with and with-
out coronary heart disease showed significantly impaired 
peripheral vascular function assessed by RHI compared 
to non-diabetic patients without coronary heart disease 
[18]. A recent study demonstrated that patients with 
T2D and diabetic foot syndrome have lower mean values 
of RHI than diabetic subjects without diabetic foot [23]. 
OSA is also associated with a decrease in endothelial NO 
synthase and an increase in endothelin-1 levels [24], with 
hypercoagulability [25], and inflammation [26]. Repeated 
hypoxemia-reoxygenation episodes induce ROS produc-
tion [27]. The final result of this process is the develop-
ment of endothelial dysfunction and micro-vascular 
impairment [28]. Several clinic-based and population-
based studies have demonstrated that OSA is associated 
with severity-dependent deterioration of endothelial 
function assessed by RHI in both adults and children 
[29–34]. Microparticles (MPs) are small plasma mem-
brane vesicles that can be released by a variety of vascular 
or blood cells and contain both membrane and cyto-
solic elements. Experimental data has demonstrated that 
MPs can promote endothelial dysfunction. MPs released 
in  vitro by apoptotic T-lymphocytes impair endothelial 
function by stimulating oxygen free radical generation, 
and decreasing Ser1179 phosphorylation of endothelial 
NO synthase [35]. Recent data suggest that circulating 
MPs released by activated endothelial cells can be con-
sidered as biomarkers of endothelial dysfunction in OSA 
[35] and in T2D [36].
In clinical practice, OSA is frequently associated with 
several risk factors for atherosclerosis, including hyper-
tension [37], T2D [38, 39] and the metabolic syndrome 
[40]. Previous studies demonstrated additive effects on 
early markers of atherosclerosis in patients with OSA 
associated with hypertension [41] or the metabolic syn-
drome [40]. There is evidence to suggest that the pres-
ence and severity of untreated OSA is associated with 
poorer glucose control in patients with T2D [38]. How-
ever, although recent data suggested that OSA may be 
associated with diabetic retinopathy [42], nephropathy 
[43] and neuropathy [44], there is no conclusive evidence 
today regarding the impact of the OSA-T2D relation on 
micro- and macro-vascular diabetic complications [45]. 
As OSA and T2D often occur concomitantly, the pres-
ence of OSA may exert addictive effects on subclinical 
markers of vascular dysfunction in patients with T2D. 
The main objective of the present study was to deter-
mine whether increasing OSA severity is associated with 
poorer endothelial function, which could contribute to 
increase the risk of micro- and macro-vascular complica-
tions in patients with T2D and no overt CV disease.
Methods
Study design
This study was cross-sectional study done in two French 
sleep centers (Angers University Hospital and Le Mans 
General Hospital, France). The study was approved by 
our local ethical committee (CPP OUEST II, no2011/12). 
Outcome assessors were unaware of study-group 
assignment.
Participants
Patients aged 18–75 with T2D on stable medications for 
the preceding 3 months, without medical history of CV 
disease including coronary heart disease, heart failure, 
arrhythmias and stroke, were recruited from the out-
patients diabetes clinics of Angers and Le Mans hospi-
tals. All patients gave their written informed consent to 
participate in the study.
Sleep studies
In all patients OSA was assessed by an overnight in-
laboratory polysomnography (PSG) (CID 102™, Cidelec, 
Angers, France) with continuous recording of the 
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following channels: electroencephalogram, electrooculo-
gram, chins electromyogram, arterial oxygen saturation, 
nasal–oral airflow, electrocardiogram, chest and abdomi-
nal wall motion, and body position. Respiratory events 
were scored manually. An apnea was defined as the com-
plete cessation of airflow and hypopnea as a decrease 
in the nasal pressure signal of at least 30% in associa-
tion with either ≥3% arterial oxygen desaturation or an 
arousal both lasting for at least 10 s [46].
Clinical evaluation
All clinical examinations and evaluations were conducted 
during the morning hours following overnight PSG. 
Clinical evaluation included anthropometric data, smok-
ing habits, medical history, and medication use. Patients 
who were previously diagnosed as hypertensive and were 
taking antihypertensive medication were considered as 
having hypertension. Daytime sleepiness was evaluated 
by the Epworth sleepiness scale (ESS) [47]. Excessive 
daytime sleepiness was defined by an ESS ≥  11. Health 
related quality of life (HRQL) was evaluated with a vali-
dated French-language version of the medical outcomes 
study 36-item short-form (SF36) [48]. Clinic blood pres-
sure (BP) was measured using a periodically calibrated 
mercury sphygmomanometer and an appropriate cuff 
size. Recorded blood pressure was the average of three 
consecutive readings during a 5-min period following at 
least 5 min of rest in the sitting position.
Assessment of micro‑vascular endothelial function
Endothelial function was assessed by digital pulse ampli-
tude, using PAT (EndoPAT®, Itamar Medical Ltd., Cae-
sarea, Israel) [4]. PAT was performed in the morning 
following PSG. Patients laid down in a quiet room with 
probes mounted on both index fingers and a blood pres-
sure cuff around the right arm above the elbow for the 
hyperemia testing. The left finger was used as the con-
trol. Finger arterial pulse wave amplitude was recorded 
throughout the protocol which included 3 consecutive 
stages each of 5 min duration: (1) baseline recording; (2) 
occlusion of the brachial artery by inflating the blood 
pressure cuff to 50  mm Hg above the baseline systolic 
pressure and (3) post-occlusion recording after deflation 
of the cuff to measure of the generated reactive hypere-
mia response. RHI was calculated as the ratio of the aver-
age amplitude of the PAT signal post-to-pre occlusion 
of the tested arm, normalized to the concurrent signal 
from the contralateral finger. A RHI value <1.67 indicated 
endothelial dysfunction [4]. The two participating cent-
ers followed the same procedure and PAT assessors were 
blinded to patient’s study group.
Biological assessment
Fasting blood samples were taken from the antecubi-
tal vein in the morning hours following overnight PSG. 
Plasma glucose, total serum cholesterol, and high-den-
sity lipoprotein serum cholesterol (HDLc) were directly 
measured in accredited laboratories using standard 
techniques. Low-density lipoprotein serum cholesterol 
(LDLc) was calculated. Glycated hemoglobin (HbA1c) 
was measured in whole blood with ion-exchange high-
performance liquid chromatography and used as a clini-
cal indicator of glucose control.
Plasma and serum samples were obtained after cen-
trifugation and stored at −80 °C for assessment of circu-
lating biomarkers of cardiovascular risk. For each ELISA 
kit, samples were assayed in duplicate. ELISA assays 
included serum levels of leptin (Human Leptin ELISA 
KIT, OKAA00022_96  W, AVIVA SYSTEMS BIOLOGY, 
San Diego, USA; detection limit = 7 pg/ml), adiponectin 
(Human Adiponectin ELISA KIT, EA2500-1, ASSAY-
PRO, St Charles, MO; detection limit = 0.3 ng/ml), high-
sensitive C-reactive protein (hs-CRP ELISA, DE740011, 
Demeditec, Germany; detection limit  =  0.02  µg/ml), 
soluble P-selectin (sP-selectin, Human P-Selectin/
CD62P, BBE6, R&D Systems Europe, Ltd., UK; detection 
limit = 0.5 ng/ml), and 8-iso-prostaglandin level (OxiSe-
lect™ 8-iso-Prostaglandin F2α ELISA Kit, STA-337, Cell 
Biolabs, INC., USA). Inter-assay and intra-assay variation 
for all the techniques used was  <10%. The homeostasis 
model assessment resistance index (HOMA-IR) was cal-
culated from fasting glucose and insulin concentrations, 
as follows: insulin (mIU/l) * glucose (mmol/l)/22.5.
In 43 patients circulating microparticles (MPs) were 
isolated from blood samples within 2 h after completion 
of sampling, from a peripheral vein using a 21-gauge nee-
dle to minimize platelet activation. A first centrifugation 
of blood was carried out 260g for 20  min. Plasma was 
centrifuged at 1500g for 20 min in order to obtain plate-
let-free plasma. Two hundred microliters of platelet-free 
plasma were frozen and stored at −80 °C for subsequent 
analysis. Circulating MPs were quantified and their cel-
lular origin identified using flow cytometry with specific 
antibodies (Beckman Coulter, Villepinte, France). Anti-
CD62P and anti-CD62E antibodies were used to identify 
P-selectin+ and E-selectin+ MPs, corresponding to MPs 
from activated platelets and activated endothelial cells, 
respectively.
Statistical analysis
The primary outcome variable was endothelial func-
tion assessed by the RHI. Secondary outcomes included 
clinic BP, biological data and HRQL questionnaires. 
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Characteristics of the study population were determined 
according to categories of apnea–hypopnea index (AHI). 
The following commonly used cut-offs for AHI were used 
to define 3 categories of disease severity: AHI  <  15 (no 
OSA or mild OSA), 15 ≤ AHI < 30 (moderate OSA), and 
AHI ≥ 30 (severe OSA). Patients with no OSA (AHI < 5) 
and patients with mild OSA (5 ≤ AHI < 15) were pooled 
in the same group. Indeed, recent epidemiological data 
demonstrated that although mild OSA (5 ≤ AHI < 15) is 
highly prevalent, most patients are asymptomatic and the 
association between mild OSA and adverse clinical out-
comes remains unproven [49]. For other physiologic indi-
ces of OSA severity, the study sample was grouped into 
quartiles of the variable. Normality of distribution was 
assessed using the Kolmogorov–Smirnov test. Continu-
ous variables with normal distribution were described 
as mean (SD) or mean (95% confidence interval [CI]). 
Univariate analysis was first used to determine which 
primary and secondary outcomes variables could be 
significantly associated with OSA severity. For continu-
ous variables, p values across AHI categories were cal-
culated by analysis of variance. The Chi square test and 
the Fischer exact test as appropriate were used for cat-
egorical variables. Multivariate regression analyses were 
then used to characterize the independent associations 
between OSA severity and outcome variables. The cor-
relation between continuous variables was assessed by 
Pearson’s correlation coefficient. All reported p-values 
were two-sided. A p value ≤0.05 was considered to indi-
cate statistical significance. All analyses were performed 
using STATA® version 13.1 (STATA Corp., College Sta-
tion, TX, USA).
Results
A flow diagram is presented in Fig.  1. Between Octo-
ber 12, 2011 and October 27 2015, 145 patients with 
T2D on stable medications and no overt CV disease 
were assessed for eligibility, 140 of whom consented 
and were enrolled in the study. Technical failure of RHI 
measurement occurred in 14 patients. Table  1 presents 
the characteristics of 126 study participants included in 
the primary outcome analysis according to OSA sever-
ity. Among 126 patients with T2D, 27 (21.4%) had AHI 
between 15 and  <30 indicating moderate OSA and 60 
(47.6%) had AHI ≥ 30 indicating severe OSA. Significant 
inter-group differences were observed only for injectable 
GLP-1 analog and insulin use.
Peripheral endothelial function and clinic blood pressure
As shown in Table 2, increasing OSA severity in patients 
with T2D was associated neither with a decrease in 
RHI value nor with an increased risk of micro-vascular 
endothelial dysfunction as defined by a RHI value <1.67. 
In a further analysis, patients were grouped into quar-
tiles of 3% oxygen desaturation index (ODI), % sleep time 
spent with oxygen saturation (SaO2)  <90% (T90), and 
time desaturation summation index (TDS) [(100%-mean 
oxygen saturation during sleep) ×  total sleep time] [50] 
in order to estimate the impact of increasing nocturnal 
hypoxemia on RHI in T2D patients. No significant asso-
ciation was observed between RHI values and increas-
ing nocturnal hypoxemia as assessed by quartiles of ODI 
(p = 0.32), T90 (p = 0.33) and TDS (p = 0.85). Univariate 
analyses showed no significant association between RHI 
and additional factors including type of oral antidiabetic 
drug, antihypertensive medications, cholesterol-lowing 
medications, and antiaggregants (data no shown). No 
difference was observed across AHI categories regard-
ing diastolic BP. In contrast, increasing OSA severity 
was associated with significantly higher systolic BP after 
adjustment for age, gender, body mass index (BMI), insu-
lin and injectable GLP-1 analog use (p = 0.03).
Biomarkers of cardiovascular risk
As shown in Table  3, increasing OSA severity was sig-
nificantly associated with lower circulating levels of adi-
ponectin (p  =  0.0009) and higher levels of sP-selectin 
(p  =  0.03) after adjusting for age, gender, BMI, insulin 
and injectable GLP-1 analog use. There was also a trend 
for a decrease in 8-isoprostane levels with increasing 
OSA severity but the difference across AHI categories 
did not reach statistical significance after adjustment for 
confounders. No significant differences were observed 
across AHI categories for other biomarkers including 
circulating MPs excepted for a trend toward an increase 
in CD62P + MPs in moderate to severe OSA (p = 0.08). 
Fig. 1 Flow diagram of subjects during the study. RHI reactive hyper-
hemia index
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A significant negative correlation was found between 
the HOMA-IR and the RHI (r  =  −0.22; p  =  0.03). No 
correlation was observed between the RHI and other 
biomarkers.
Daytime sleepiness and quality of life questionnaires
As shown in Table  4, increasing OSA severity was 
associated with higher ESS (p  =  0.01) although the 
association was attenuated after adjustment for con-
founders (p  =  0.08). After adjustment for age, gender, 
BMI, insulin and injectable GLP-1 analog use, increasing 
OSA severity was associated lower scores in 3 domains of 
HRQL including energy/vitality (p = 0.02), role function-
ing (p =  0.01), and social functioning (p =  0.04). There 
was no significant association between RHI and ESS 
score.
Table 1 Characteristics of study participants according to obstructive sleep apnea severity
Data are expressed as mean (standard deviation) or percentages
BMI body mass index, DPP-4 dipeptidyl peptidase-4, ACE angiotensin converting enzyme, CCBs calcium channel blockers, AHI apnea–hypopnea index, ODI 3% 
oxygen desaturation index, T90 % sleep time spent with oxygen saturation <90%, TDS time desaturation summation index [(100% − mean oxygen saturation during 
sleep) × total sleep time] [50]
All AHI < 15 15 ≤ AHI < 30 AHI > 30 p value
n 126 39 27 60 –
Age, years 59.3 (9.5) 59.6 (10.6) 61.4 (10.4) 58.1 (8.3) 0.33
Women, % 40.3 51.3 36.0 35.0 0.24
BMI, kg/m2 33.2 (6.3) 32.0 (6.4) 32.5 (6.2) 34.4 (6.1) 0.14
Waist circumference, cm 113.0 (17.0) 108.0 (18.9) 115.2 (16.6) 115.3 (15.9) 0.22
Waist-to-hip ratio 1.2 (0.4) 1.1 (0.3) 1.3 (0.4) 1.3 (0.5) 0.19
Current smokers, % 13.5 18.8 14.3 7.1 0.42
Hypertension, % 59.0 46.2 66.7 64.4 0.14
Duration of diabetes, years 9.0 (7.7) 10.1 (7.4) 10.4 (8.7) 7.7 (7.3) 0.20
Metformin, % 90.3 87.1 94.7 90.7 0.83
Sulfonylurea, % 26.7 24.0 27.8 27.9 0.93
DPP-4 inhibitors, % 19.8 25.0 16.7 17.5 0.70
Injectable GLP-1 analog, % 9.6 3.7 0.0 18.0 0.01
Insulin, % 13.1 10.3 29.2 8.5 0.03
Antihypertensive medications
 ACE inhibitors, % 32.9 28.6 25.0 39.0 0.50
 CCBs, % 17.1 7.7 6.3 27.5 0.05
 β-blockers, % 23.2 32.1 16.7 20.0 0.38
 Cholesterol-lowering drugs, % 61.4 56.7 58.8 65.9 0.71
 Antiaggregants, % 14.5 18.5 11.8 12.8 0.76
Sleep-disordered breathing indices
 AHI, n 33.7 (27.5) 7.1 (4.3) 21.9 (4.0) 56.2 (23.3) <0.0001
 ODI, n 34.2 (45.7) 10.7 (17.9) 21.7 (16.6) 54.8 (56.3) <0.0001
 T90, % 54.0 (75.8) 30.8 (58.1) 35.2 (32.0) 77.9 (92.2) <0.0001
 TDS, min. 55.2 (17.6) 52.0 (16.5) 53.4 (10.2) 58.1 (20.4) 0.22
Table 2 Endothelial function and clinic blood pressure (BP) according to obstructive sleep apnea severity
Data are expressed as mean (standard deviation) or percentages
RHI reactive hyperemia index
* p values were adjusted for age, gender, body mass index, insulin and injectable GLP-1 analog use
AHI < 15 15 ≤ AHI < 30 AHI > 30 p value p value*
RHI 1.84 (0.53) 1.81 (0.55) 1.84 (0.42) 0.97 –
RHI < 1.67,  % 47.1 44.4 39.2 0.76 –
Systolic BP, mmHg 129.2 (12.5) 140.2 (17.9) 136.6 (18.0) 0.04 0.03
Diastolic BP, mmHg 76.6 (8.9) 78.4 (9.6) 80.9 (12.1) 0.15 –
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Discussion
The main finding of the present study is the lack of addi-
tive effect of OSA severity on endothelial dysfunction 
in patients with T2D. Increasing OSA severity and noc-
turnal hypoxemia were not associated with a significant 
decrease in RHI. In contrast, increasing OSA severity 
was associated with higher systolic BP, lower circulating 
levels of adiponectin and higher levels of sP-selectin.
The present study confirms the very high prevalence 
of OSA in patients with T2D. Moderate to severe OSA 
Table 3 Biochemical variables according to obstructive sleep apnea severity
Data are expressed as mean (standard deviation)
HbA1C glycated hemoglobin, HOMA-IR homeostasis model assessment of insulin resistance, TC total cholesterol, HDLc high-density lipoprotein cholesterol, LDLc low-
density lipoprotein cholesterol, TG triglycerides, hs-CRP high-sensitivity C-reactive protein, sP-sel soluble P-selectin, MPs microparticles
* p values were adjusted for age, gender, body mass index, insulin and injectable GLP-1 analog use
AHI < 15 15 ≤ AHI < 30 AHI > 30 p value p value*
HbA1C,  % 8.0 (1.7) 7.3 (1.4) 7.4 (1.2) 0.05 –
Glucose, mmol/l 8.4 (2.2) 7.8 (2.3) 7.9 (1.9) 0.34 –
Insulin, mU/l 15.3 (11.2) 22.2 (25.0) 15.0 (10.4) 0.11 –
HOMA-IR 5.6 (4.9) 8.1 (9.5) 5.3 (3.9) 0.13 –
TC, mmol/l 4.6 (1.0) 4.6 (1.3) 4.6 (0.8) 0.99 –
HDLc, mmol/l 1.1 (0.2) 1.0 (0.2) 1.0 (0.2) 0.18 –
LDLc, mmol/l 2.7 (1.0) 2.9 (1.3) 2.7 (0.5) 0.88 –
TG, mmol/l 1.7 (0.9) 1.6 (0.6) 2.3 (1.3) 0.18 –
Adiponectin, µg/ml 14.7 (7.1) 9.2 (6.3) 9.3 (6.4) 0.0004 0.0009
Leptin, ng/ml 30.9 (20.5) 38.8 (34.2) 33.5 (25.9) 0.54 –
Leptin/adiponectin 3.5 (3.8) 5.4 (5.1) 5.5 (6.5) 0.19 –
8-isoprostane, pg/ml 401.7 (142.8) 235.7 (157.4) 304.1 (195.1) 0.01 0.09
hs-CRP, µg/ml 45.1 (60.7) 30.7 (30.7) 40.3 (35.8) 0.45 –
sP-sel, ng/ml 38.4 (17.9) 54.9 (36.9) 50.8 (25.6) 0.03 0.03
Circulating MPs (n = 43)
 CD62E+ MPs/ml 70.4 (45.4) 113.2 (116.5) 76.0 (66.6) 0.3882 –
 CD62P+ MPs/250 × 103platelets/ml 37.3 (22.7) 54.8 (41.2) 64.1 (37.4) 0.0838 –
Table 4 Daytime sleepiness and quality of life questionnaires according to obstructive sleep apnea severity
Data are expressed as mean (standard deviation) or percentages
ESS Epworth sleepiness scale, PSQI Pittsburgh sleep quality index, PCS physical component score, MCS mental component score
* p values were adjusted for age, gender, body mass index, insulin and injectable GLP-1 analog use
AHI < 15 15 ≤ AHI < 30 AHI > 30 p value p value*
Daytime sleepiness
 ESS 7.5 (4.3) 8.5 (5.3) 10.6 (5.3) 0.01 0.08
 ESS ≥ 11, % 22.8 37.5 46.0 0.06 –
Quality of life
 SF36 PCS 50.4 (2.3) 50.6 (2.5) 51.0 (2.2) 0.51 –
 SF36 MCS 48.1 (5.9) 47.0 (6.5) 45.4 (6.4) 0.12 –
 SF36 bodily pain 60.4 (24.7) 60.9 (29.2) 54.1 (26.0) 0.41 –
 SF36 energy/vitality 57.1 (20.8) 52.1 (25.9) 43.0 (23.8) 0.02 0.02
 SF36 general health 65.6 (21.8) 62.3 (18.2) 56.2 (22.0) 0.11 –
 SF36 mental health 67.6 (20.3) 63.5 (23.1) 57.8 (22.0) 0.09 –
 SF36 physical functioning 72.3 (25.8) 65.4 (27.3) 62.5 (28.3) 0.24
 SF36 role emotional 82.1 (34.1) 76.0 (35.4) 65.1 (42.0) 0.10 –
 SF36 role physical 83.3 (30.5) 66.0 (40.1) 58.0 (40.7) 0.007 0.01
 SF36 social functioning 75.5 (28.7) 76.6 (25.7) 61.6 (31.1) 0.03 0.04
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prevalence in our sample of subjects with T2D (69.0%) 
was even higher than in previous studies [38, 39]. Among 
305 obese patients with T2D, Foster et  al. [39] found 
53.1% of patients with moderate to severe OSA. However, 
the authors used the 2007 American Academy of Sleep 
Medicine (AASM) respiratory event criteria that were 
recently demonstrated to underestimate the AHI when 
compared to 2012 AASM criteria [51]. In a more recent 
study including 234 patients with T2D, 151 patients had 
OSA on home-based cardiorespiratory sleep study of 
whom only 40% had moderate to severe OSA [38]. How-
ever, a recent report from the multi-center European 
Sleep Apnea Cohort (ESADA) demonstrated that car-
diorespiratory sleep studies interpreted using standard 
guidelines result in under diagnosis and misclassification 
of OSA [52].
Despite the high prevalence of OSA in patients with 
T2D, the impact of OSA severity on micro-vascular 
endothelial function in diabetic subjects has not been 
clearly elucidated. In a cross-sectional study including 
healthy normal-weight controls (n =  14), healthy obese 
controls (n = 33), subjects with T2D (n = 68), and obese 
subjects with OSA (n  =  38), Yim-Yeh et  al. [53] con-
cluded that OSA impaired endothelial function in the 
brachial artery as assessed by FMD to a similar degree as 
T2D did. However, OSA patients compared to patients 
with T2D displayed a better vascular reactivity in the skin 
microcirculation on laser Doppler flowmetry after ace-
tylcholine iontophoresis. This study was not designed to 
evaluate an additive effect of OSA severity on endothe-
lial dysfunction. Furthermore T2D patients had no sleep 
study and it is likely that many of these patients had undi-
agnosed OSA. More recently, Tahrani et al. [38] studied 
micro-vascular function by laser speckle contrast imag-
ing in patients with T2D with OSA (n = 47) and without 
OSA (n  =  24). After adjustment for confounders, OSA 
was associated with impairments in basal micro-vascular 
flux and endothelial-independent micro-vascular reac-
tivity (sodium nitroprusside) but not with endothelial-
dependent micro-vascular reactivity (acetylcholine). We 
acknowledge the lack of healthy control group in our 
study. In a recent study including 53 healthy subjects 
with a mean BMI of 25 (4.3) kg/m2, the mean RHI value 
was 2.4 (0.6) [23]. In a recent randomized controlled trial 
including 150 patients with severe OSA (median [inter-
quartile range] AHI, 41.0 [35.0–53.0]; mean BMI, 27.0 
(3.2) kg/m2), with no overt CV disease and only 5% of 
comorbid TD2, the mean RHI value was 2.15 (0.61) [54]. 
The mean RHI value in our population of diabetic sub-
jects was markedly lower [≈1.8 (0.5)] with no difference 
across AHI categories. Altogether, our findings and those 
of previous studies suggest that TD2 has major adverse 
effects on endothelial function and that endothelial 
dysfunction could not be made any worse by OSA. The 
lack of difference in MPs from activated endothelial cells 
(CD62E  +  MPs) across AHI categories also reinforced 
the notion that OSA does not aggravate endothelial dys-
function in T2D patients. This result is consistent with 
findings of a recent study demonstrating the lack of asso-
ciation between OSA and endothelial function assessed 
by RHI in obese subjects [55]. Endothelial dysfunction is 
linearly associated with dysglycemia even in the absence 
of overt diabetes [56, 57]. Our results are also partially 
consistent with findings of recent randomized trials 
showing that CPAP therapy of OSA has no effect on gly-
cemic control in patients with TD2 [58], and does not 
prevent CV events in patients with established CV dis-
ease [59].
Oxidative stress and concomitant systemic inflamma-
tion are two of the prominent underlying mechanisms 
suggested to contribute to the increased risk for CV dis-
ease both in OSA [60] and T2D [61]. In the present study, 
there was a trend for a decrease in 8-isoprostane levels 
with increasing OSA severity although the inter-group 
difference did not reach statistical significance after 
adjustment for confounders. Despite the general belief 
that OSA increases oxidative stress, a recent randomized 
controlled study has demonstrated a reduction in urinary 
F2-isoprostane after 2 weeks of intermittent hypoxia fol-
lowing continuous positive airway pressure (CPAP) with-
drawal [62]. CPAP withdrawal was also associated with 
a rise in plasma superoxide dismutase, an antioxidant 
known to be increased by hypoxic preconditioning. Para-
doxical data from epidemiological mortality endpoint 
studies also supported the existence of protective precon-
ditioning effects in OSA [60]. Further studies are required 
to investigate potential protective effects of OSA against 
oxidative stress in T2D. Among various adipokines, adi-
ponectin has attracted considerable attention due to its 
role in CV disorders. It has been suggested that reduced 
serum adiponectin levels could partly explain increased 
CV disease in OSA patients [63]. Interestingly, increas-
ing OSA severity in our sample of patients with T2D was 
associated with a significant reduction in adiponectin 
levels after adjustment for confounding factors including 
BMI. P-selectin is an adhesion molecule that is expressed 
on activated platelets and endothelium and is shed into 
plasma in a soluble form, sP-selectin [64]. P-selectin is 
involved in leukocyte rolling and attachment, and thus 
can play an important role in the initiation of atheroscle-
rosis [65]. Serum levels of sP-selectin were found to be 
increased in moderate to severe OSA patients and were 
associated with a higher prevalence of silent brain infarc-
tion on brain magnetic resonance images [66]. In the pre-
sent study, moderate to severe OSA was associated with 
elevated levels of sP-selectin in patients with T2D. There 
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was also a trend toward an increase in MPs derived from 
activated platelets (CD62P+) in moderate to severe OSA. 
Although we failed to demonstrate a significant corre-
lation between RHI, adiponectin and sP-selectin, both 
might contribute to increase the risk of CV events in 
T2D patients with moderate to severe OSA.
Our study has some strengths and limitations. The 
major strengths include the availability of PSG data, 
which is the gold standard for OSA diagnosis, and 
endothelial function assessment in a relatively large sam-
ple of patients. The major limitation of our study is its 
cross-sectional design and the lack of an interventional 
arm. Further studies are required to determine whether 
low RHI values predict poorer CV outcomes in patients 
with OSA and T2D. In the present study we investigated 
peripheral endothelial function at the level of the arte-
rioles, which are most importantly related to peripheral 
vascular resistance [67, 68]. Although changes in pulse 
wave amplitude during reactive hyperemia were found to 
be correlated with brachial artery FMD [11, 12], the NO-
mediated component totals ≈60% of digital artery dila-
tion, whereas the remainder represents other vasodilator 
components [69]. It cannot be excluded that the findings 
would have been different if we used a different method 
for vascular function assessment. For example noctur-
nal non-dipping, a typical BP pattern in OSA [70], has 
been found to be associated with nitroglycerin-mediated 
vasodilation but not with FMD [71]. However, there is 
strong evidence that PAT is a reliable and reproducible 
technique to accurately characterize endothelial func-
tion in multicenter studies [3–7, 72]. A recent review [3] 
suggested that micro-vascular function might be more 
relevant in subjects without overt CV disease and may 
be an earlier indicator of CV risk than macrovascular 
function assessed by FMD. From a technical viewpoint, 
PAT offers the advantages of being less prone to opera-
tor error than FMD [69]. We acknowledge that we did 
not evaluate fluctuations in glucose levels by continuous 
glucose monitoring in the present study. Indeed, fluctu-
ations in blood glucose levels were found to play a sig-
nificant role in vascular endothelial dysfunction assessed 
by RHI in TD2 [73]. Nocturnal hyperglycemia has been 
reported in patients with TD2 and OSA particulary dur-
ing REM sleep apneas with marked oxygen desaturations 
[74]. However, no significant association was observed 
between RHI values and increasing nocturnal hypoxemia 
in the present study.
Conclusion
Moderate to severe OSA is very common but has no 
impact on digital micro-vascular endothelial function in 
patients with T2D.
Abbreviations
AHI: apnea–hypopnea index; BMI: body mass index; BP: blood pressure; CV: 
cardiovascular; ESS: Epworth sleepiness scale; FMD: flow-mediated dilata-
tion; HbA1c: glycated hemoglobin; HDLc: high-density lipoprotein serum 
cholesterol; HOMA-IR: homeostasis model assessment resistance index; HRQL: 
health related quality of life; LDLc: low-density lipoprotein serum cholesterol; 
NO: nitric oxyde; ODI: 3% oxygen desaturation index; OSA: obstructive sleep 
apnea; PAT: peripheral arterial tonometry; PSQI: Pittsburgh sleep quality index; 
PSG: polysomnography; T2D: type 2 diabetes; T90: % sleep time spent with 
oxygen saturation (SaO2) <90%; RHI: reactive hyperemia index; SF36: medical 
outcomes study 36-item short-form.
Authors’ contributions
FG, MCM, MLV, PA, PHD, RA,VB Researched data, contributed to iscussion, 
wrote the manuscript, reviewed/edited the manuscript. AP, CS, FG, PP, SH, 
SD, NM, WT researched data, contributed to discussion, reviewed/edited the 
manuscript. All authors read and approved the final manuscript.
Author details
1 Université Bretagne Loire, INSERM UMR 1063, Angers, France. 2 Ser-
vice de Pneumologie, Centre Hospitalier, Le Mans, France. 3 Unité 
d’Endocrinologie-Diabétologie-Nutrition, Pole de Médecine, CHRU de Tours, 
Tours, France. 4 Centre de Recherche Médecine, Sciences, Santé, Santé 
mentale, Société, CNRS UMR 8211, INSERM UMR U988-EHESS, Villejuif, France. 
5 Département de Médecine du Sport et Explorations Fonctionnelles Vas-
culaires, Université Bretagne Loire, CHU d’Angers, Angers, France. 6 Départe-
ment d’Endocrinologie, Diabétologie, Nutrition, Université Bretagne Loire, 
CHU d’Angers, Angers, France. 7 Département de Pneumologie, Université 
Bretagne Loire, CHU d’Angers, 4 Rue Larrey, 49100 Angers, France. 8 Service 
d’Endocrinologie, Diabétologie, Centre Hospitalier, Le Mans, France. 
Acknowledgements
The authors thank Jean-Marie Chrétien, Caroline Erignoux and Anaïg Le 
Cam, for their help with study monitoring, and coordination, as well as data 
management.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Ethics and consent to participate
The investigations were carried out in accordance with the Declaration of 
Helsinki, including written informed consent from all participants. The study 
was approved by our local ethical committee (CPP OUEST II, no2011/12).
Funding
This work was funded by the Institut de Recherche en Santé Respiratoire (IRSR) 
des Pays de la Loire (9 rue du landreau-BP 77132-49071 Beaucouzé cedex, 
France).
Received: 4 February 2017   Accepted: 15 March 2017
References
 1. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, 
Finkel T. Circulating endothelial progenitor cells, vascular function, and 
cardiovascular risk. N Engl J Med. 2003;348(7):593–600.
 2. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, 
Ferraro A, Chello M, Mastroroberto P, Verdecchia P, et al. Prognostic sig-
nificance of endothelial dysfunction in hypertensive patients. Circulation. 
2001;104(2):191–6.
 3. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz 
P, Hamburg NM, Luscher TF, Shechter M, Taddei S, et al. The assessment 
Page 9 of 10Bironneau et al. Cardiovasc Diabetol  (2017) 16:39 
of endothelial function: from research into clinical practice. Circulation. 
2012;126(6):753–67.
 4. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. 
Noninvasive identification of patients with early coronary atheroscle-
rosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 
2004;44(11):2137–41.
 5. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, 
Ohba K, Matsubara J, Maeda H, Horibata Y, et al. Incremental prognostic 
significance of peripheral endothelial dysfunction in patients with heart 
failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 
2012;60(18):1778–86.
 6. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper 
GM, Lerman LO, Lerman A. Assessment of endothelial function by 
non-invasive peripheral arterial tonometry predicts late cardiovascular 
adverse events. Eur Heart J. 2010;31(9):1142–8.
 7. Matsuzawa Y, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Konishi M, 
Matsubara J, Sumida H, Kaikita K, Kojima S, et al. Digital assessment of 
endothelial function and ischemic heart disease in women. J Am Coll 
Cardiol. 2010;55(16):1688–96.
 8. Tuttolomondo A, Casuccio A, Della Corte V, Maida C, Pecoraro R, Di 
Raimondo D, Vassallo V, Simonetta I, Arnao V, Pinto A. Endothelial func-
tion and arterial stiffness indexes in subjects with acute ischemic stroke: 
relationship with TOAST subtype. Atherosclerosis. 2017;256:94–9.
 9. Tuttolomondo A, Pecoraro R, Di Raimondo D, Di Sciacca R, Canino 
B, Arnao V, Butta C, Della Corte V, Maida C, Licata G, et al. Immune-
inflammatory markers and arterial stiffness indexes in subjects with acute 
ischemic stroke with and without metabolic syndrome. Diabetol Metab 
Syndr. 2014;6(1):28.
 10. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role 
of nitric oxide in the regulation of digital pulse volume amplitude in 
humans. J Appl Physiol. 2006;101(2):545–8.
 11. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, 
Udelson JE. Assessment of peripheral vascular endothelial function with 
finger arterial pulse wave amplitude. Am Heart J. 2003;146(1):168–74.
 12. Dhindsa M, Sommerlad SM, DeVan AE, Barnes JN, Sugawara J, Ley O, Tan-
aka H. Interrelationships among noninvasive measures of postischemic 
macro- and microvascular reactivity. J Appl Physiol. 2008;105(2):427–32.
 13. Hamburg NM, Palmisano J, Larson MG, Sullivan LM, Lehman BT, Vasan RS, 
Levy D, Mitchell GF, Vita JA, Benjamin EJ. Relation of brachial and digital 
measures of vascular function in the community: the Framingham heart 
study. Hypertension. 2011;57(3):390–6.
 14. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, Dejgaard A, Lau-
ritzen M, Lauritzen E, Hougaard P, et al. Prevalence of micro- and macroal-
buminuria, arterial hypertension, retinopathy and large vessel disease in 
European type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 
1991;34(9):655–61.
 15. Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J. The 
endothelin receptor antagonist bosentan improves peripheral endothe-
lial function in patients with type 2 diabetes mellitus and microalbumi-
nuria: a randomised trial. Diabetologia. 2012;55(3):600–7.
 16. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular 
disease: pathophysiology, clinical consequences, and medical therapy: 
part I. Circulation. 2003;108(12):1527–32.
 17. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin 
resistance syndrome. J Intern Med. 2000;247(4):425–31.
 18. Gargiulo P, Marciano C, Savarese G, D’Amore C, Paolillo S, Esposito G, 
Santomauro M, Marsico F, Ruggiero D, Scala O, et al. Endothelial dysfunc-
tion in type 2 diabetic patients with normal coronary arteries: a digital 
reactive hyperemia study. Int J Cardiol. 2013;165(1):67–71.
 19. Jenkins DJ, Kendall CW, Vuksan V, Faulkner D, Augustin LS, Mitchell S, Ire-
land C, Srichaikul K, Mirrahimi A, Chiavaroli L, et al. Effect of lowering the 
glycemic load with canola oil on glycemic control and cardiovascular risk 
factors: a randomized controlled trial. Diabetes Care. 2014;37(7):1806–14.
 20. Kwak JH, Paik JK, Kim HI, Kim OY, Shin DY, Kim HJ, Lee JH, Lee JH. Dietary 
treatment with rice containing resistant starch improves markers of 
endothelial function with reduction of postprandial blood glucose and 
oxidative stress in patients with prediabetes or newly diagnosed type 2 
diabetes. Atherosclerosis. 2012;224(2):457–64.
 21. Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y. Impact 
of teneligliptin on oxidative stress and endothelial function in type 2 
diabetes patients with chronic kidney disease: a case-control study. 
Cardiovasc Diabetol. 2016;15:76.
 22. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, 
Maeda H, Fujisue K, Yamamoto E, Kaikita K, et al. Dipeptidyl peptidase-4 
inhibitor, sitagliptin, improves endothelial dysfunction in association with 
its anti-inflammatory effects in patients with coronary artery disease and 
uncontrolled diabetes. Circ J. 2013;77(5):1337–44.
 23. Tuttolomondo A, Casuccio A, Guercio G, Maida C, Del Cuore A, Di Rai-
mondo D, Simonetta I, Di Bona D, Pecoraro R, Della Corte V, et al. Arterial 
stiffness, endothelial and cognitive function in subjects with type 2 dia-
betes in accordance with absence or presence of diabetic foot syndrome. 
Cardiovasc Diabetol. 2017;16(1):2.
 24. Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor PH, Le 
Jemtel TH. Vascular inflammation in obesity and sleep apnea. Circulation. 
2010;121(8):1014–21.
 25. Toraldo DM, De Benedetto M, Scoditti E, De Nuccio F. Obstructive sleep 
apnea syndrome: coagulation anomalies and treatment with continuous 
positive airway pressure. Sleep Breath. 2016;20(2):457–65.
 26. Arias MA, Garcia-Rio F, Alonso-Fernandez A, Hernanz A, Hidalgo R, Mar-
tinez-Mateo V, Bartolome S, Rodriguez-Padial L. CPAP decreases plasma 
levels of soluble tumour necrosis factor-alpha receptor 1 in obstructive 
sleep apnoea. Eur Respir J. 2008;32(4):1009–15.
 27. Alonso-Fernandez A, Garcia-Rio F, Arias MA, Hernanz A, de la Pena M, 
Pierola J, Barcelo A, Lopez-Collazo E, Agusti A. Effects of CPAP on oxidative 
stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax. 
2009;64(7):581–6.
 28. Sanchez-de-la-Torre M, Campos-Rodriguez F, Barbe F. Obstructive sleep 
apnoea and cardiovascular disease. Lancet Respir Med. 2013;1(1):61–72.
 29. Azuma M, Chihara Y, Yoshimura C, Murase K, Hamada S, Tachikawa R, 
Matsumoto T, Inouchi M, Tanizawa K, Handa T, et al. Association between 
endothelial function (assessed on reactive hyperemia peripheral arterial 
tonometry) and obstructive sleep apnea, visceral fat accumulation, and 
serum adiponectin. Circ J. 2015;79(6):1381–9.
 30. Itzhaki S, Lavie L, Pillar G, Tal G, Lavie P. Endothelial dysfunction in obstruc-
tive sleep apnea measured by peripheral arterial tone response in the 
finger to reactive hyperemia. Sleep. 2005;28(5):594–600.
 31. Kheirandish-Gozal L, Etzioni T, Bhattacharjee R, Tan HL, Samiei A, Molero 
Ramirez H, Abu Eta B, Pillar G. Obstructive sleep apnea in children is asso-
ciated with severity-dependent deterioration in overnight endothelial 
function. Sleep Med. 2013;14(6):526–31.
 32. Randby A, Namtvedt SK, Hrubos-Strom H, Einvik G, Somers VK, Omland 
T. Sex-dependent impact of OSA on digital vascular function. Chest. 
2013;144(3):915–22.
 33. Seif F, Patel SR, Walia H, Rueschman M, Bhatt DL, Gottlieb DJ, Lewis EF, 
Patil SP, Punjabi NM, Babineau DC, et al. Association between obstruc-
tive sleep apnea severity and endothelial dysfunction in an increased 
background of cardiovascular burden. J Sleep Res. 2013;22(4):443–51.
 34. Olafiranye O, Kip KE, Rhinehart Z, Mulukutla SR, Aiyer A, Strollo PJ, Reis SE. 
Impact of race and obesity on arterial endothelial dysfunction associ-
ated with sleep apnea: results from the Heart SCORE study. Int J Cardiol. 
2015;201:476–8.
 35. Trzepizur W, Martinez MC, Priou P, Andriantsitohaina R, Gagnadoux F. 
Microparticles and vascular dysfunction in obstructive sleep apnoea. Eur 
Respir J. 2014;44(1):207–16.
 36. Agouni A, Andriantsitohaina R, Martinez MC. Microparticles as biomarkers 
of vascular dysfunction in metabolic syndrome and its individual compo-
nents. Curr Vasc Pharmacol. 2014;12(3):483–92.
 37. Torres G, Sanchez-de-la-Torre M, Barbe F. Relationship between OSA and 
hypertension. Chest. 2015;148(3):824–32.
 38. Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated 
obstructive sleep apnea on glucose control in type 2 diabetes. Am J 
Respir Crit Care Med. 2010;181(5):507–13.
 39. Foster GD, Sanders MH, Millman R, Zammit G, Borradaile KE, Newman 
AB, Wadden TA, Kelley D, Wing RR, Sunyer FX, et al. Obstructive sleep 
apnea among obese patients with type 2 diabetes. Diabetes Care. 
2009;32(6):1017–9.
 40. Drager LF, Bortolotto LA, Maki-Nunes C, Trombetta IC, Alves MJ, Fraga 
RF, Negrao CE, Krieger EM, Lorenzi-Filho G. The incremental role of 
obstructive sleep apnoea on markers of atherosclerosis in patients with 
metabolic syndrome. Atherosclerosis. 2010;208(2):490–5.
Page 10 of 10Bironneau et al. Cardiovasc Diabetol  (2017) 16:39 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 41. Drager LF, Bortolotto LA, Krieger EM, Lorenzi-Filho G. Additive effects of 
obstructive sleep apnea and hypertension on early markers of carotid 
atherosclerosis. Hypertension. 2009;53(1):64–9.
 42. Banerjee D, Leong WB, Arora T, Nolen M, Punamiya V, Grunstein R, Taheri 
S. The potential association between obstructive sleep apnea and 
diabetic retinopathy in severe obesity-the role of hypoxemia. PLoS ONE. 
2013;8(11):e79521.
 43. Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Altaf QA, Piya MK, Bar-
nett AH, Stevens MJ. Obstructive sleep apnea and diabetic nephropathy: 
a cohort study. Diabetes Care. 2013;36(11):3718–25.
 44. Tahrani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, Jose B, Piya 
MK, Barnett AH, Stevens MJ. Obstructive sleep apnea and diabetic neu-
ropathy: a novel association in patients with type 2 diabetes. Am J Respir 
Crit Care Med. 2012;186(5):434–41.
 45. Greco C, Spallone V. Obstructive sleep apnoea syndrome and dia-
betes. Fortuitous Association or Interaction? Curr Diabetes Rev. 
2015;12(2):129–55.
 46. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, 
Mehra R, Parthasarathy S, Quan SF, et al. Rules for scoring respiratory 
events in sleep: update of the 2007 AASM Manual for the Scoring of 
Sleep and Associated Events. Deliberations of the Sleep Apnea Defini-
tions Task Force of the American Academy of Sleep Medicine. J Clin Sleep 
Med. 2012;8(5):597–619.
 47. Johns MW. A new method for measuring daytime sleepiness: the 
Epworth sleepiness scale. Sleep. 1991;14(6):540–5.
 48. Perneger TV, Leplege A, Etter JF, Rougemont A. Validation of a French-
language version of the MOS 36-Item Short Form Health Survey (SF-36) 
in young healthy adults. J Clin Epidemiol. 1995;48(8):1051–60.
 49. McNicholas WT, Bonsignore MR, Levy P, Ryan S. Mild obstructive sleep 
apnoea: clinical relevance and approaches to management. Lancet 
Respir Med. 2016;4(10):826–34.
 50. Sawatari H, Chishaki A, Nishizaka M, Tokunou T, Adachi S, Yoshimura C, 
Ohkusa T, Ando S. Cumulative hypoxemia during sleep predicts vascular 
endothelial dysfunction in patients with sleep-disordered breathing. Am 
J Hypertens. 2016;29(4):458–63.
 51. Duce B, Milosavljevic J, Hukins C. The 2012 AASM respiratory event 
criteria increase the incidence of hypopneas in an adult sleep Center 
population. J Clin Sleep Med. 2015;11(12):1425–31.
 52. Escourrou P, Grote L, Penzel T, McNicholas WT, Verbraecken J, Tkacova 
R, Riha RL, Hedner J, Group ES. The diagnostic method has a strong 
influence on classification of obstructive sleep apnea. J Sleep Res. 
2015;24(6):730–8.
 53. Yim-Yeh S, Rahangdale S, Nguyen AT, Stevenson KE, Novack V, Veves A, 
Malhotra A. Vascular dysfunction in obstructive sleep apnea and type 2 
diabetes mellitus. Obesity (Silver Spring). 2011;19(1):17–22.
 54. Gagnadoux F, Pepin JL, Vielle B, Bironneau V, Chouet-Girard F, Lau-
nois S, Meslier N, Meurice JC, Nguyen XL, Paris A, et al. Impact of 
mandibular advancement therapy on endothelial function in severe 
obstructive sleep apnea. Am J Respir Crit Care Med. 2017. doi:10.1164/
rccm.201609-1817OC.
 55. Araujo Lda S, Fernandes JF, Klein MR, Sanjuliani AF. Obstructive sleep 
apnea is independently associated with inflammation and insulin 
resistance, but not with blood pressure, plasma catecholamines, and 
endothelial function in obese subjects. Nutrition. 2015;31(11–12):1351–7.
 56. Hanis CL, Redline S, Cade BE, Bell GI, Cox NJ, Below JE, Brown EL, Aguilar 
D. Beyond type 2 diabetes, obesity and hypertension: an axis including 
sleep apnea, left ventricular hypertrophy, endothelial dysfunction, and 
aortic stiffness among Mexican Americans in Starr County, Texas. Cardio-
vasc Diabetol. 2016;15:86.
 57. Rodriguez CJ, Miyake Y, Grahame-Clarke C, Di Tullio MR, Sciacca RR, 
Boden-Albala B, Sacco RL, Homma S. Relation of plasma glucose and 
endothelial function in a population-based multiethnic sample of sub-
jects without diabetes mellitus. Am J Cardiol. 2005;96(9):1273–7.
 58. Shaw JE, Punjabi NM, Naughton MT, Willes L, Bergenstal RM, Cistulli PA, 
Fulcher GR, Richards GN, Zimmet PZ. the effect of treatment of obstruc-
tive sleep apnea on glycemic control in type 2 diabetes. Am J Respir Crit 
Care Med. 2016;194(4):486–92.
 59. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen 
R, Drager LF, Liu Z, et al. CPAP for prevention of cardiovascular events in 
obstructive sleep apnea. N Engl J Med. 2016;375(10):919–31.
 60. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent 
hypoxia–revisited–the bad ugly and good: implications to the heart and 
brain. Sleep Med Rev. 2015;20:27–45.
 61. Kayama Y, Raaz U, Jagger A, Adam M, Schellinger IN, Sakamoto M, Suzuki 
H, Toyama K, Spin JM, Tsao PS. Diabetic cardiovascular disease induced by 
oxidative stress. Int J Mol Sci. 2015;16(10):25234–63.
 62. Stradling JR, Schwarz EI, Schlatzer C, Manuel AR, Lee R, Antoniades C, 
Kohler M. Biomarkers of oxidative stress following continuous positive 
airway pressure withdrawal: data from two randomised trials. Eur Respir J. 
2015;46(4):1065–71.
 63. Chen LD, Liu JN, Lin L, Wu Z, Li H, Ye YM, Xu QZ, Lin QC. Effect of continu-
ous positive airway pressure on adiponectin in patients with obstructive 
sleep apnea: a meta-analysis. PLoS ONE. 2015;10(9):e0136837.
 64. Wagner DD. The Weibel-Palade body: the storage granule for von Wille-
brand factor and P-selectin. Thromb Haemost. 1993;70(1):105–10.
 65. Dong ZM, Brown AA, Wagner DD. Prominent role of P-selectin in the 
development of advanced atherosclerosis in ApoE-deficient mice. Circu-
lation. 2000;101(19):2290–5.
 66. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Oda N, Tanaka A, Yama-
moto M, Ohta S, O’Donnell CP, Adachi M. Silent brain infarction and 
platelet activation in obstructive sleep apnea. Am J Respir Crit Care Med. 
2007;175(6):612–7.
 67. Schiffrin EL. Remodeling of resistance arteries in essential hypertension 
and effects of antihypertensive treatment. Am J Hypertens. 2004;17(12 Pt 
1):1192–200.
 68. Simpson PJ, Hoyos CM, Celermajer D, Liu PY, Ng MK. Effects of continuous 
positive airway pressure on endothelial function and circulating progeni-
tor cells in obstructive sleep apnoea: a randomised sham-controlled 
study. Int J Cardiol. 2013;168(3):2042–8.
 69. Lian BQ, Keaney JF Jr. Predicting ischemic heart disease in women: the 
value of endothelial function. J Am Coll Cardiol. 2010;55(16):1697–9.
 70. Parati G, Lombardi C, Hedner J, Bonsignore MR, Grote L, Tkacova R, Levy P, 
Riha R, Bassetti C, Narkiewicz K, et al. Recommendations for the manage-
ment of patients with obstructive sleep apnoea and hypertension. Eur 
Respir J. 2013;41(3):523–38.
 71. Fontes-Guerra PC, Cardoso CR, Muxfeldt ES, Salles GF. Nitroglycerin-
mediated, but not flow-mediated vasodilation, is associated with blunted 
nocturnal blood pressure fall in patients with resistant hypertension. J 
Hypertens. 2015;33(8):1666–75.
 72. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Cre-
ager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al. 
Guidelines for the ultrasound assessment of endothelial-dependent flow-
mediated vasodilation of the brachial artery: a report of the International 
Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257–65.
 73. Torimoto K, Okada Y, Mori H, Tanaka Y. Relationship between fluctua-
tions in glucose levels measured by continuous glucose monitoring and 
vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc 
Diabetol. 2013;12:1.
 74. Fendri S, Rose D, Myambu S, Jeanne S, Lalau JD. Nocturnal hyperglycae-
mia in type 2 diabetes with sleep apnoea syndrome. Diabetes Res Clin 
Pract. 2011;91(1):e21–3.
